Aileron Therapeutics, Inc. Obtains $10,000,000 New Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9abbb5c3-e03d-4ec6-a407-d4e48c16733d&Preview=1
Date
12/31/2007
Company Name
Aileron Therapeutics, Inc.
Mailing Address
840 Memorial Drive Cambridge, MA 02139
Company Description
Aileron Therapeutics is an emerging biopharmaceutical company that is applying its proprietary cell permeable peptide technology to generate breakthrough therapeutics
for the treatment of cancer and other diseases. Aileron’s technology is the first and
only process that allows peptides to penetrate cells in a sequence-independent manner. Aileron is developing the first generation of peptide therapeutics directed at intra-cellular protein-protein interaction targets that are not addressable by small molecule or biological drugs.
Website
http://www.aileronrx.com
Transaction Type
Venture Equity
Transaction Amount
$10,000,000
Transaction Round
Undisclosed
Proceeds Purposes
Proceeds purposes were not disclosed.
M&A Terms
Venture Investor
Apple Tree Partners
Venture Investor
Novartis BioVenture Fund
Venture Investor
Undisclosed